2 active not recruiting, 2 not yet recruiting, 1 completed, 1 recruiting. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Active not recruiting 2, Not yet recruiting 2, Completed 1 |
| Phase 2 | 4 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Unknown 1 |
Follow Beijing Gene Key Life Technology Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of GKL-006RTU in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) GKL-006RTU injection, Placebo - ARDS (Acute Respiratory Distress Syndrome) | Phase 1 / Phase 2 | Not yet recruiting | Beijing Gene Key Life Technology Co., Ltd | 52 | 2026-11-10 | 2026-09-30 |
| GKL-006Allo Injection in Patients With Advanced Solid Tumors GKL-006Allo Injection - Solid Tumor Malignancies | Phase 1 | Not yet recruiting | Beijing Gene Key Life Technology Co., Ltd | 27 | 2026-08-30 | 2026-07-15 |
| GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, TACE - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 2 | Recruiting | Beijing Gene Key Life Technology Co., Ltd | 48 | 2025-11-14 | 2026-08-17 |
| A Phase I/IIa Study of GKL-006 Injection in Patients With Advanced Pancreatic Cancer GKL-006 injection, Nab-paclitaxel and Gemcitabine - Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas | Phase 1 / Phase 2 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 52 | 2025-08-14 | 2026-08-20 |
| A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma GKL-006 Injection, Transarterial chemoembolization (TACE) - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Cancer | Phase 1 | Active not recruiting | Beijing Gene Key Life Technology Co., Ltd | 6 | 2025-04-03 | 2026-07-20 |
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GKL-006 Injection in Combination With TACE in Unresectable Hepatocellular Carcinoma GKL-006 Injection, transarterial chemoembolization - Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma | Phase 1 | Completed | Beijing Gene Key Life Technology Co., Ltd | 13 | 2024-04-16 | 2026-09-28 |
| Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy iNKT Cells, PD-1, Regorafenib - Hepatocellular Carcinoma | Phase 2 | Unknown | Beijing YouAn Hospital | 84 | 2023-10-26 | 2024-01-16 |
Carcinoma, Hepatocellular (4) · Acute Lung Injury (1)
130-nm albumin-bound paclitaxel (1) · Gemcitabine (1) · regorafenib (1)
China (6)
Gaojun Teng, MD (1) · Jun Lu, MD. (1) · Jun Lv, MD (1) · Ning Li, MD (1)